Investment Rating - The report maintains a positive outlook on the overseas education sector, particularly highlighting key companies in the education and training industry [1]. Core Insights - The overseas education sector has shown significant improvement in operational efficiency, with a focus on key companies in the education and training industry [1]. - New Oriental (09901.HK) reported a revenue of $1.191 billion for Q2 FY26, a year-on-year increase of 14.7%, with a Non-GAAP net profit of $73 million, reflecting a 68.6% increase [6]. - Oriental Selection (01797.HK) achieved a revenue of 2.31 billion yuan in 1H FY26, up 5.7% year-on-year, and turned a profit with a net profit of 239 million yuan [9]. Summary by Sections 1. Overseas Education - The education index surged by 7.2% in the week of January 23-29, outperforming the Hang Seng Index by 2.2 percentage points [5]. - New Oriental's education business (including cultural tourism) generated $974 million, a 13% increase year-on-year, while other businesses (mainly Oriental Selection) saw a 22.9% revenue growth [6]. - The study abroad business's revenue growth has stabilized, with a 1% increase year-on-year, although it has slowed compared to previous periods [6]. 2. Oriental Selection - The company reported a revenue of 2.31 billion yuan in 1H FY26, marking a 5.7% increase year-on-year, and achieved profitability with a net profit of 239 million yuan [9]. - The gross merchandise volume (GMV) from self-operated products reached 2.16 billion yuan, with a significant improvement in gross margin from 21.5% to 33.7% year-on-year [10]. - The company is expanding its product offerings and enhancing operational efficiency, with a focus on increasing the utilization rate of existing teaching sites [7]. 3. Overseas Pharmaceuticals - The report highlights a strategic R&D collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at $18.5 billion, focusing on innovative long-acting peptide drugs [3][19]. - The agreement includes a $1.2 billion upfront payment and potential milestone payments totaling up to $13.8 billion, along with sales royalties based on net sales [19]. 4. Overseas Social Services - Macau's gaming revenue maintained double-digit growth, with December's gross gaming revenue reaching 20.9 billion MOP, a 14.8% year-on-year increase [23]. - The total visitor count for Macau in 2025 reached 40.06 million, a 14.7% increase year-on-year, marking a historical high [23].

Investment Rating - The report does not explicitly state an investment rating for CSPC Pharmaceutical Group Core Insights - CSPC Pharmaceutical Group has entered into a strategic collaboration and licensing agreement with AstraZeneca, focusing on innovative peptide molecule discovery and the development of long-acting delivery products [1][7] - AstraZeneca will receive exclusive global rights (excluding certain regions) to develop, manufacture, and commercialize innovative long-acting peptide drugs based on CSPC's technology platforms [2][8] - The collaboration includes a total upfront payment of USD 1.2 billion, with milestone payments potentially reaching up to USD 35 billion for development and USD 138 billion for sales [3][9][10] - This partnership marks the third collaboration between CSPC and AstraZeneca, highlighting CSPC's competitive edge in innovative drug development [4][11] Summary by Sections Collaboration Framework - AstraZeneca will develop and commercialize long-acting peptide drugs globally, excluding Mainland China and certain regions [2][8] - The collaboration will also involve four additional new projects based on the existing technology platforms [2][8] Financial Terms - Upfront Payment: AstraZeneca will pay a total of USD 1.2 billion, with CSPC Jushi Biomedicine receiving 35% of this amount [3][9] - Milestone Payments: Up to USD 3.5 billion for development milestones and up to USD 13.8 billion for sales milestones [3][9][10] - Royalties: AstraZeneca will pay tiered royalties up to the low-double digits on net sales of all licensed products [10] Company Pipeline and Future Outlook - CSPC's pipeline includes high-quality assets such as EGFR ADC, PDE4B inhibitors, and monoclonal antibodies, with over 20 innovative drug assets entering clinical stages annually [4][12] - The collaboration is expected to enhance AstraZeneca's competitiveness in the long-acting GLP-1R space, benefiting both companies [4][11]

Core Insights - AstraZeneca has announced a collaboration with China National Pharmaceutical Group (CSPC) for a licensing agreement valued at up to $18.5 billion, focusing on the development of obesity and diabetes medications [1][2] - The partnership will leverage CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform to jointly develop innovative long-acting peptide drugs [1] - This agreement marks CSPC's largest business development deal to date, with potential total payments reaching $18.5 billion if all milestones are achieved [2] Financial Aspects - CSPC will receive an upfront payment of $1.2 billion, with the potential for up to $3.5 billion in research milestone payments and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [1][2] - The deal is expected to significantly support AstraZeneca's pipeline for obesity drugs, which currently includes three candidates at various stages of development [5] Market Context - The global obesity drug market is projected to reach $100 billion by 2030, indicating a rapidly growing sector where AstraZeneca aims to compete against established players like Novo Nordisk and Eli Lilly [5] - The collaboration is part of a broader trend where multinational pharmaceutical companies are increasingly investing in the Chinese market, driven by the need for high-quality drug pipelines amid patent expirations and declining R&D efficiency [6][7] Strategic Importance - AstraZeneca plans to invest $15 billion in the Chinese market by 2030 to enhance its capabilities in drug production and R&D, which is crucial for achieving its goal of launching 20 innovative drugs by that year [6] - The partnership with CSPC is seen as a complement to AstraZeneca's investment strategy in China, reinforcing its commitment to local innovation and development [6] Industry Trends - By 2025, China's innovative drug licensing transactions are expected to exceed $130 billion, reflecting a significant increase in the number of deals and the value of Chinese biotech assets [7] - The shift from simple licensing to more complex collaborations indicates that Chinese pharmaceutical companies are poised to capture a larger share of the global pharmaceutical value chain [7][8]

Core Viewpoint - AstraZeneca has announced a collaboration with China National Pharmaceutical Group (CSPC) to develop obesity and diabetes drugs, with a maximum value of $18.5 billion, aiming to strengthen its position in a rapidly growing market [1][2]. Group 1: Collaboration Details - The agreement allows AstraZeneca exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, produce, and commercialize a weight management product portfolio, including one project entering clinical trials and three preclinical projects [1]. - CSPC will receive a $1.2 billion upfront payment, with potential milestone payments of up to $3.5 billion for development and $13.8 billion for sales, plus a double-digit percentage royalty based on annual net sales of the licensed products [1][2]. Group 2: Market Context - If all milestones are achieved, CSPC could receive a total of $18.5 billion, making it the largest business development deal for the company to date [2]. - The deal is expected to surpass recent significant transactions in the obesity drug market, including Pfizer's acquisition of a weight loss drug startup for over $10 billion [5]. Group 3: Strategic Importance - This collaboration supports AstraZeneca's pipeline for obesity drugs, with three treatments currently in various stages of development, and positions the company to compete in a market dominated by Novo Nordisk and Eli Lilly [5]. - Analysts predict that the global obesity drug market could reach $100 billion by 2030, highlighting the strategic importance of this collaboration for AstraZeneca [5]. Group 4: Investment in China - AstraZeneca plans to invest $15 billion in the Chinese market by 2030 to enhance its capabilities in drug production and research, which is crucial for achieving its goal of launching 20 innovative drugs by 2030 [6]. - The partnership with CSPC is seen as a complement to this investment strategy, reflecting the increasing focus of multinational pharmaceutical companies on the Chinese market [6]. Group 5: Industry Trends - The Chinese pharmaceutical market is experiencing a surge in innovation, with projections indicating that by 2025, the total value of innovative drug licensing transactions will exceed $130 billion [7]. - The industry is evolving from simple licensing agreements to more complex collaborations, allowing Chinese pharmaceutical companies to capture a larger share of the global pharmaceutical value chain [7][8].

Core Viewpoint - The strategic collaboration between Shijiazhuang Pharmaceutical Group and AstraZeneca marks a significant milestone in the outbound business development (BD) of Chinese innovative drugs, with a potential total payment of up to $18.5 billion, setting a new record for BD transactions in the Chinese pharmaceutical industry [1][3]. Group 1: Transaction Details - Shijiazhuang Pharmaceutical has signed a strategic R&D cooperation and licensing agreement with AstraZeneca, utilizing its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform to develop innovative long-acting peptide drugs [1]. - The total potential payment of $18.5 billion includes an upfront payment of $1.2 billion, with the remaining $17.3 billion contingent on achieving various R&D and sales milestones over the coming years [3]. Group 2: Market Reaction - Despite the significant deal, Shijiazhuang Pharmaceutical's stock experienced a sharp decline, dropping nearly 13% intraday and closing down 10.2%, attributed to profit-taking after a strong pre-announcement stock performance [1][3]. - The overall market sentiment was also negative, with major indices in Hong Kong, including the Hang Seng Index and the Hang Seng Biotechnology Index, falling over 2%, impacting the performance of other leading Chinese biopharmaceutical companies [3]. Group 3: Industry Outlook - Analysts suggest that the core logic of domestic innovative drugs remains solid, indicating a favorable window for investment as the BD of Chinese companies accelerates and the price gap for innovative drugs between China and the U.S. narrows, presenting significant long-term growth potential [5]. - The Hong Kong Stock Connect innovative drug ETF (520880) has seen substantial net subscriptions, indicating ongoing investor interest despite recent market volatility [4].

Group 1: Market Overview - The Hong Kong stock market saw a net inflow of 32.22 billion HKD from northbound trading, with 20.39 billion HKD from Shanghai and 11.83 billion HKD from Shenzhen [1] - The most bought stocks included CSPC Pharmaceutical Group (01093), Xiaomi Group-W (01810), and the Tracker Fund of Hong Kong (02800) [1] Group 2: Notable Stock Transactions - CSPC Pharmaceutical Group (01093) received a net inflow of 9.36 billion HKD, following a strategic cooperation agreement with AstraZeneca for the development of innovative long-acting peptide drugs, potentially worth up to 18.5 billion USD [4] - The Tracker Fund of Hong Kong (02800) saw a net inflow of 5.89 billion HKD, with positive market sentiment driven by earnings recovery, improved liquidity, low valuations, and policy support [5] - Alibaba Group-W (09988) had a net inflow of 3.29 billion HKD, as it launched a high-end AI chip, enhancing its position in the AI technology sector [5] - Longi Green Energy Technology (06869) experienced a net inflow of 2.41 billion HKD, driven by strong demand for AI infrastructure and optical communication upgrades [5] Group 3: Stocks with Significant Net Outflows - Shandong Gold (01787) and Zijin Mining (02899) faced net outflows of 2.06 billion HKD and 6.35 billion HKD respectively, amid significant volatility in the precious metals market [7] - Semiconductor manufacturer SMIC (00981) saw a net outflow of 545.8 million HKD, with limited impact expected from the approval of H200 chips for the domestic market [7] - Xiaomi Group-W (01810) had a net inflow of 9.14 billion HKD, while China Mobile (00941) and CNOOC (00883) faced net outflows of 5.41 billion HKD and 5.25 billion HKD respectively [7]

Core Viewpoint - The strategic research and development collaboration agreement between Stone Pharmaceutical Group and AstraZeneca aims to leverage Stone's proprietary sustained-release drug delivery technology and AI drug discovery platform for innovative long-acting peptide drugs, with a potential total value of up to $18.5 billion [1] Group 1: Financial Aspects - The collaboration includes an upfront payment of $1.2 billion to Stone Pharmaceutical Group [1] - Potential milestone payments for research could reach up to $3.5 billion, while sales milestone payments could be as high as $13.8 billion [1] - Stone will also receive a double-digit percentage royalty based on the annual net sales of the licensed products [1] Group 2: Market Reaction - Following the announcement, Stone Pharmaceutical Group's stock price fell by 10.2%, closing at HKD 9.6 per share [1] - The A-share company, XinNuoWei, experienced a decline of 15.72%, closing at CNY 38.87 per share [1]

Group 1 - The net inflow of southbound funds today amounted to 3.22 billion HKD [1] - The top three companies with net inflows were CSPC Pharmaceutical Group, Xiaomi Group-W, and the Tracker Fund of Hong Kong, with net purchases of 935 million HKD, 914 million HKD, and 590 million HKD respectively [1] - The companies with the highest net outflows included Zijin Mining, China Mobile, and CNOOC, with net sales of 635 million HKD, 541 million HKD, and 526 million HKD respectively [1]

Group 1 - Southbound funds net bought Hong Kong stocks worth 32.22 billion HKD today [1] - The top net purchases included: CSPC Pharmaceutical Group at 9.34 billion HKD, Xiaomi Group-W at 9.14 billion HKD, and the Tracker Fund of Hong Kong at 5.89 billion HKD [1] - Notable net sales included: Zijin Mining at 6.35 billion HKD, China Mobile at 5.41 billion HKD, and CNOOC at 5.25 billion HKD [1] Group 2 - Southbound funds have recorded a continuous net sell of China Mobile for 20 days, totaling 159.752 billion HKD [1] - Zijin Mining has seen a net sell for 5 consecutive days, amounting to 37.8638 billion HKD [1] - Semiconductor Manufacturing International Corporation (SMIC) has also experienced a net sell for 5 consecutive days, totaling 12.2751 billion HKD [1]

Group 1 - Sanofi's net profit is expected to reach 2.9 billion yuan in 2025, with a significant increase primarily due to a payment of approximately 2.89 billion yuan from Pfizer for a licensing agreement [1] - The company's projected revenue for 2025 is around 4.2 billion yuan, reflecting an increase of approximately 3.006 billion yuan, or 251.76% year-on-year [1] - The net profit attributable to shareholders is anticipated to rise by 2.195 billion yuan, marking a growth of 311.35% compared to the previous year [1] Group 2 - Ruiang Gene's actual controllers, Xiong Hui and Xiong Jun, have been arrested on charges of fraud, but this will not significantly impact the company's daily operations [2] - The company maintains a robust corporate governance structure and internal control system, ensuring that business management continues normally [2] Group 3 - Insilico Medicine has entered into a strategic drug development collaboration with Qilu Pharmaceutical, with a total contract value exceeding 931 million Hong Kong dollars [3] - The collaboration will focus on the development of small molecule inhibitors for cardiovascular and metabolic diseases using Insilico's Pharma.AI platform [3] Group 4 - AstraZeneca plans to invest over 100 billion yuan (15 billion USD) in China by 2030 to enhance its drug production and R&D capabilities [4] - The investment aims to leverage China's scientific innovation and advanced manufacturing strengths to deliver cutting-edge therapies to patients [4] Group 5 - Takeda Pharmaceutical has appointed Liu Yan as the new president of Takeda China, responsible for overall strategy and business development [5] - Liu Yan has over 15 years of experience in the pharmaceutical industry and has been instrumental in accelerating global product introductions and exploring innovative business models [5] Group 6 - CSPC Pharmaceutical has signed a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs, with a total deal value potentially reaching 18.5 billion USD [6][7] - The agreement includes a 1.2 billion USD upfront payment and potential milestone payments of up to 3.5 billion USD for R&D and 13.8 billion USD for sales [7]